M
Michael S. Gordon
Researcher at Loyola University Chicago
Publications - 200
Citations - 10251
Michael S. Gordon is an academic researcher from Loyola University Chicago. The author has contributed to research in topics: Tolerability & Cancer. The author has an hindex of 40, co-authored 200 publications receiving 8878 citations.
Papers
More filters
Journal ArticleDOI
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Journal ArticleDOI
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
David F. McDermott,Meredith M. Regan,Joseph I. Clark,Lawrence E. Flaherty,Geoffery R. Weiss,T. Logan,John M. Kirkwood,Michael S. Gordon,Jeffrey A. Sosman,Marc S. Ernstoff,Christopher P.G. Tretter,Walter J. Urba,John W. Smith,Kim Margolin,James W. Mier,Jared Gollob,Janice P. Dutcher,Michael B. Atkins +17 more
TL;DR: This randomized phase III trial provides additional evidence that HD IL-2 should remain the preferred therapy for selected patients with metastatic renal cell carcinoma.
Journal ArticleDOI
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.
Leisha A. Emens,Leisha A. Emens,Cristina Cruz,Joseph Paul Eder,Fadi Braiteh,Cathie Chung,Sara M. Tolaney,Irene Kuter,Rita Nanda,Philippe A. Cassier,Jean Pierre Delord,Michael S. Gordon,Ehab Elgabry,Ching-Wei Chang,Indrani Sarkar,William Grossman,Carol O'Hear,Marcella Fassò,Luciana Molinero,Peter Schmid +19 more
TL;DR: Single-agent atezolizumab was well tolerated and provided durable clinical benefit in patients with mTNBC with stable or responding disease and in earlier lines of treatment.
Journal ArticleDOI
Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer
David B. Agus,Michael S. Gordon,Charles T. Taylor,Ronald B. Natale,Beth Y. Karlan,David S. Mendelson,Michael F. Press,David E. Allison,Mark X. Sliwkowski,Gracie Lieberman,Stephen Michael Kelsey,Gwen Fyfe +11 more
TL;DR: It is demonstrated that pertuzumab is well tolerated, has a pharmacokinetic profile which supports 3-week dosing, and is clinically active, suggesting that inhibition of dimerization may be an effective anticancer strategy.
Journal ArticleDOI
Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer
Roy S. Herbst,S. Gail Eckhardt,Razelle Kurzrock,Scot Ebbinghaus,Peter J. O'Dwyer,Michael S. Gordon,William Novotny,Meredith A. Goldwasser,Tanyifor M. Tohnya,Bert L. Lum,Avi Ashkenazi,Adrian M. Jubb,David S. Mendelson +12 more
TL;DR: Dose escalation achieved peak rhApo2L/TRAIL serum concentrations equivalent to those associated with preclinical antitumor efficacy, and the first in-human clinical trial to assess the safety, tolerability, pharmacokinetics, and antitumors activity of multiple intravenous doses of rhA po2L /TRAil in patients with advanced cancer was safe and well tolerated.